Testing a new antidote for severe side effects from chemo
Part of Cancer clinical trials.
This trial tests a new antidote for people who have had severe or life-threatening side effects from fluorouracil or capecitabine chemotherapy. It aims to help the body recover faster and reduce harm from these drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a severe side effect (like serious nausea, diarrhea, fever with low white blood cells, or mouth sores) from fluorouracil or capecitabine chemo, or received too much of the drug.
- You do not have access to the standard antidote (uridine triacetate).
- You have a solid tumor cancer and are being treated with fluorouracil or capecitabine.
- You can take pills by mouth.
- Your kidneys and liver are working well enough (specific blood and urine tests will check this).
- You are not pregnant or breastfeeding, and you agree to use birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
This trial is testing a new combination therapy for people with advanced solid tumors. The goal is to see if it helps shrink tumors or slows their growth.
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.